Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation of [14C]HSK31858 in Healthy Chinese Men
NCT06569784Phase 1Active, not recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HSK31858 in bronchiectasis, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Total radioactivity recovery rates in urine, Total radioactivity recovery rates in feces and 4 more. Started May 2024; status: active, not recruiting.
02
Drugs
HSK31858
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT06569784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569784.